Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States of America.
AstraZeneca, 430 East 29 Street, New York, NY 10016, United States of America.
Clin Imaging. 2024 Jun;110:110134. doi: 10.1016/j.clinimag.2024.110134. Epub 2024 Mar 22.
To explore pre-treatment imaging findings of neurotrophic tyrosine receptor kinase (NTRK)-rearranged spindle cell neoplasm, an emerging group of molecularly defined soft tissue tumors and summarize the clinical course, including TRK inhibitor therapy response.
This retrospective study included 8 women and 4 men with NTRK-rearranged spindle cell neoplasm (median age, 35.5 years, range, 0-66). Available pre-treatment MRI, CT, PET, and US imaging were reviewed. Tumor histology and the patients' clinical course were reviewed.
Primary tumors were located within the soft tissue, lungs, kidney, and breast with soft tissue being the most prevalent site (n = 6). Pre-treatment MRI (n = 4) revealed linear hypointense signal foci and contrast enhancement in all patients with hemorrhage in half of the tumors. A tail sign (n = 1) and fluid levels (n = 1) were less frequent. Ultrasound showed well-marginated hypoechoic masses with internal flow. Primary tumors were all non-calcified on CT (4/4). Metastases were FDG-avid (4/4). Among the 8 patients who developed metastasis, 7 developed pulmonary metastases. All four patients who received NTRK inhibitor therapy showed an initial decrease in tumor size or FDG uptake.
NTRK-rearranged neoplasms may occur as enhancing masses with linear hypointense signal foci on MRI and FDG avid metastases on PET. Pulmonary metastases were frequent in our study. Initial treatment response is observed in most patients.
探讨神经酪氨酸受体激酶(NTRK)重排梭形细胞肿瘤的术前影像学表现,该肿瘤是一组新兴的分子定义的软组织肿瘤,并总结其临床病程,包括 TRK 抑制剂治疗的反应。
本回顾性研究纳入了 8 名女性和 4 名男性 NTRK 重排梭形细胞肿瘤患者(中位年龄 35.5 岁,范围 0-66 岁)。回顾分析了术前 MRI、CT、PET 和 US 影像学资料。评估了肿瘤组织学和患者的临床病程。
原发性肿瘤位于软组织、肺、肾和乳腺,其中软组织最常见(n=6)。术前 MRI(n=4)显示所有患者均有线性低信号灶和增强,半数肿瘤有出血。尾征(n=1)和液性平片(n=1)较少见。超声显示边界清楚的低回声肿块,内部有血流。CT 上所有原发性肿瘤均无钙化(n=4/4)。转移灶均 FDG 摄取增高(n=4/4)。在发生转移的 8 名患者中,有 7 名发生了肺部转移。所有接受 NTRK 抑制剂治疗的 4 名患者均表现出肿瘤体积或 FDG 摄取的初始减小。
NTRK 重排肿瘤可能在 MRI 上表现为强化肿块,伴线性低信号灶,在 PET 上表现为 FDG 摄取增高的转移灶。在本研究中,肺部转移较为常见。大多数患者可观察到初始治疗反应。